ArticleCurrent microbiology2025
Complete Genome Sequence, Biological Activities, and Metabolomic Profiles of Mangrove-Derived Streptomyces sp. SM1P.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The genome of Streptomyces sp. SM1P was sequenced to give a contig of 7,561,428 bp (71.7% G + C content) and 24 putative secondary metabolite biosynthetic gene clusters (BGCs). Eight of the BGCs showed high similarity (≥ 80%), three have moderate similarity (between 50 and 79%), and eleven showed low similarity (less than 50%) to known BGCs. The strain was cultivated in 7 different media prepared in 3 different solvents and the secondary metabolites were extracted with ethyl acetate to give 21 different extracts. All extracts showed antimicrobial and cytotoxic activities, with extracts from the ISP1/NaCl and ISP4/ASW cultures were the most active against bacteria and brine shrimp nauplii, respectively. The extract of the ISP2/NaCl culture, which gave a high number of spots on TLC, was also active against Plasmodium berghei. Untargeted metabolomic analysis of the ISP1/NaCl, ISP2/NaCl, and ISP4/ASW extracts using gas chromatography-mass spectrometry (GC-MS) and comparisons of the data against the National Institute of Standards and Technology 20 Mass Spectral Library showed variations between their secondary metabolites. Principal Component Analysis of the m/z values showed a correlation between ISP1/NaCl and ISP2/NaCl but not with ISP4/ASW. Metabolomic analysis of ISP2/NaCl extract using liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) and comparisons of the data with those in the GNPS database and others indicated the presence of a lankamycin derivative (an antibiotic) and a cyclosporin derivative (an immunosuppressant). However, many other metabolites did not have a match. The results showed that Streptomyces sp. SM1P has potential as a producer of new secondary metabolites, particularly those with antimicrobial and antitumor activities.
Indexed as
Identifiers
40085245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.